# Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma

> **NCT04605185** · PHASE1 · UNKNOWN · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 18 (estimated)

## Conditions studied

- Unresectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** Donafenib Tosilate Tablets
- **BIOLOGICAL:** Toripalimab Injection

## Key facts

- **NCT ID:** NCT04605185
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-08
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04605185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04605185, "Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04605185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*